Novartis Ag Adr Stock Fundamentals
| NVS Stock | USD 98.35 1.07 1.10% |
Novartis AG ADR fundamentals help investors to digest information that contributes to Novartis' financial success or failures. It also enables traders to predict the movement of Novartis Stock. The fundamental analysis module provides a way to measure Novartis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novartis stock.
At this time, Novartis' Net Income From Continuing Ops is comparatively stable compared to the past year. Tax Provision is likely to gain to about 1.7 B in 2024, whereas Interest Expense is likely to drop slightly above 550.6 M in 2024. Novartis | Select Account or Indicator |
Novartis AG ADR Company Return On Equity Analysis
Novartis' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Novartis Return On Equity | 0.2 |
Most of Novartis' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Novartis Return On Equity Historical Pattern
Today, most investors in Novartis Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Novartis' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's return on equity growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Novartis return on equity as a starting point in their analysis.
Novartis Return On Equity |
| Timeline |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Novartis Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Novartis AG ADR has a Return On Equity of 0.1983. This is 100.83% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all United States stocks is 163.97% lower than that of the firm.
Novartis AG ADR Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Novartis's current stock value. Our valuation model uses many indicators to compare Novartis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novartis competition to find correlations between indicators driving Novartis's intrinsic value. More Info.Novartis AG ADR is rated below average in return on equity category among related companies. It is regarded fifth in return on asset category among related companies reporting about 0.44 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Novartis AG ADR is roughly 2.29 . At this time, Novartis' Return On Equity is comparatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Novartis by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Novartis' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novartis' earnings, one of the primary drivers of an investment's value.Novartis Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.Novartis is currently under evaluation in return on equity category among related companies.
Novartis Fundamentals
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0865 | ||||
| Profit Margin | 0.32 % | ||||
| Operating Margin | 0.31 % | ||||
| Current Valuation | 216.21 B | ||||
| Shares Outstanding | 2.04 B | ||||
| Shares Owned By Institutions | 6.92 % | ||||
| Number Of Shares Shorted | 4.21 M | ||||
| Price To Earning | 9.22 X | ||||
| Price To Book | 4.10 X | ||||
| Price To Sales | 4.14 X | ||||
| Revenue | 46.66 B | ||||
| Gross Profit | 36.74 B | ||||
| EBITDA | 18.47 B | ||||
| Net Income | 8.57 B | ||||
| Cash And Equivalents | 4.64 B | ||||
| Cash Per Share | 8.84 X | ||||
| Total Debt | 26.35 B | ||||
| Debt To Equity | 0.47 % | ||||
| Current Ratio | 1.31 X | ||||
| Book Value Per Share | 19.45 X | ||||
| Cash Flow From Operations | 14.46 B | ||||
| Short Ratio | 2.77 X | ||||
| Earnings Per Share | 4.10 X | ||||
| Price To Earnings To Growth | 5.09 X | ||||
| Target Price | 113.07 | ||||
| Number Of Employees | 76.06 K | ||||
| Beta | 0.48 | ||||
| Market Capitalization | 198.95 B | ||||
| Total Asset | 99.94 B | ||||
| Retained Earnings | 49.65 B | ||||
| Working Capital | 4.09 B | ||||
| Current Asset | 22.84 B | ||||
| Current Liabilities | 23.71 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 3.53 % | ||||
| Net Asset | 99.94 B | ||||
| Last Dividend Paid | 3.92 |
About Novartis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 98 M | 135.9 M | |
| Total Revenue | 46.7 B | 46.2 B | |
| Cost Of Revenue | 12.5 B | 13.9 B | |
| Stock Based Compensation To Revenue | 0.02 | 0.02 | |
| Sales General And Administrative To Revenue | 0.36 | 0.37 | |
| Research And Ddevelopement To Revenue | 0.24 | 0.13 | |
| Capex To Revenue | (0.06) | (0.06) | |
| Revenue Per Share | 22.47 | 14.31 | |
| Ebit Per Revenue | 0.21 | 0.18 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Novartis Piotroski F Score and Novartis Altman Z Score analysis. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.215 | Dividend Share 3.919 | Earnings Share 4.1 | Revenue Per Share 23.168 | Quarterly Revenue Growth 0.097 |
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.